基于检查点抑制剂免疫治疗的预测性生物标志物
综述讨论PD-L1检测作为检查点抑制剂预测生物标志物的现状与不足,并探索肿瘤浸润淋巴细胞、突变负荷、免疫基因特征及多重免疫组化等新兴策略。未来有效生物标志物的开发需整合多种方法以全面刻画免疫肿瘤微环境。
要点
- PD-L1阳性可富集临床获益人群,但多数恶性肿瘤中单用PD-L1检测不足以筛选患者。
- PD-1或PD-L1单药耐受性通常良好,联合方案则增加免疫相关不良事件风险。
- 肿瘤浸润淋巴细胞、突变负荷、免疫基因特征与多重免疫组化是新兴生物标志物方向。
核心结论
- 未来有效的检查点抑制剂预测生物标志物需整合多种方法,以实现对免疫肿瘤微环境的最佳刻画。
研究设计与样本
- 本文为综述,讨论PD-L1检测现状并探索肿瘤浸润淋巴细胞、突变负荷、免疫基因特征和多重免疫组化等新兴生物标志物策略。
主要发现
- PD-L1阳性可富集临床获益人群,但多数恶性肿瘤中单用PD-L1检测不足以筛选患者。
- PD-1或PD-L1单药通常耐受良好,联合方案的免疫相关不良事件风险增加。
局限性
- 多数恶性肿瘤中单用PD-L1检测不足以用于患者筛选。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The clinical development of checkpoint inhibitor-based immunotherapy has ushered in an exciting era of anticancer therapy. Durable responses can be seen in patients with melanoma and other malignancies. Although monotherapy with PD-1 or PD-L1 agents are typically well tolerated, the risk of immune-related adverse events increases with combination regimens. The development of predictive biomarkers is needed to optimise patient benefit, minimise risk of toxicities, and guide combination approaches. The greatest focus has been on tumour-cell PD-L1 expression. Although PD-L1 positivity enriches for populations with clinical benefit, PD-L1 testing alone is insufficient for patient selection in most malignancies. In this Review, we discuss the status of PD-L1 testing and explore emerging data on new biomarker strategies with tumour-infiltrating lymphocytes, mutational burden, immune gene signatures, and multiplex immunohistochemistry. Future development of an effective predictive biomarker for checkpoint inhibitor-based immunotherapy will integrate multiple approaches for optimal characterisation of the immune tumour microenvironment.
引用
- Gibney GT, Weiner LM, Atkins MB, et al. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016. PMID: 27924752. doi:10.1016/S1470-2045(16)30406-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。